RLMD (Relmada Therapeutics) ROCE %: -50.22% (As of Mar. 2026)


RLMD Relmada Therapeutics Inc RLMD
29 GF Score
Price $6.67
! 2 Warning Signs
View Full Analysis

What is Relmada Therapeutics ROCE %?

Relmada Therapeutics RLMD +3.72% 29 ROCE % is -50.22% as of Mar. 2026. GuruFocus rates RLMD with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Relmada Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -50.22%.

Relmada Therapeutics  (NAS:RLMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Relmada Therapeutics ROCE % Related Terms

Relmada Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Relmada Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relmada Therapeutics ROCE % Chart

Relmada Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -80.10 -92.49 -91.86 -138.80 -96.02

Relmada Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -251.39 -212.78 -321.88 -167.25 -50.22
RLMD
29GF Score
Relmada Therapeutics Inc RLMD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relmada Therapeutics ROCE % Calculation

Relmada Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-59.1/( ( (45.818 - 10.291) + (94.003 - 6.431) )/ 2 )
=-59.1/( (35.527+87.572)/ 2 )
=-59.1/61.5495
=-96.02 %

Relmada Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-77.848/( ( (94.003 - 6.431) + (235.363 - 12.892) )/ 2 )
=-77.848/( ( 87.572 + 222.471 )/ 2 )
=-77.848/155.0215
=-50.22 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -50.22% mean?
Relmada Therapeutics (RLMD) has a ROCE % of -50.22% as of Mar. 2026.
Is Relmada Therapeutics' ROCE % too high?
Relmada Therapeutics' current ROCE % is -50.22%. Overall, Relmada Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Relmada Therapeutics' ROCE % compare to ALLO and PHAT?
Relmada Therapeutics' ROCE % of -50.22% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Relmada Therapeutics's current ROCE % is -50.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relmada Therapeutics stock overvalued right now?
Relmada Therapeutics (RLMD) has a current ROCE % of -50.22%. The current ROCE % is -50.22%. Relmada Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Relmada Therapeutics (RLMD), the current ROCE % is -50.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Relmada Therapeutics Business Description

Other Exchanges 4E2:Germany
Address 2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
29GF Score

Get the complete analysis for RLMD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.67
Price